Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Rocket Pharmaceuticals Inc shares valued at $15,978 were sold by Militello John on Nov 21 ’24. At $13.05 per share, Militello John sold 1,224 shares. The insider’s holdings dropped to 49,310 shares worth approximately $0.58 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Patel Kinnari sold 4,588 shares, netting a total of over 59,892 in proceeds. Following the sale of shares at $13.05 each, the insider now holds 392,395 shares.
Before that, Shah Gaurav had sold 11,091 shares from its account. In a trade valued at $144,782, the CEO traded Rocket Pharmaceuticals Inc shares for $13.05 each. Upon closing the transaction, the insider’s holdings decreased to 11,091 shares, worth approximately $8.3 million.
As published in their initiating research note from Jefferies on December 18, 2024, Rocket Pharmaceuticals Inc [RCKT] has been a Buy and the price target has been revised to $29. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in mid October. As of April 02, 2024, Goldman has initiated its “Neutral” rating for RCKT. Earlier on October 24, 2023, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for RCKT stock.
Analyzing RCKT Stock Performance
During the last five days, there has been a drop of approximately -12.19%. Over the course of the year, Rocket Pharmaceuticals Inc shares have dropped approximately -60.83%. Shares of the company reached a 52-week high of $31.47 on 02/27/24 and a 52-week low of $11.58 on 12/17/24. A 50-day SMA is recorded $15.37, while a 200-day SMA reached $20.45. Nevertheless, trading volume fell to 1.99 million shares from 1.15 million shares the previous day.
Support And Resistance Levels for Rocket Pharmaceuticals Inc (RCKT)
According to the 24-hour chart, there is a support level at 11.35, which, if violated, would cause prices to drop to 10.96. In the upper region, resistance lies at 12.50. The next price resistance is at 13.26. RSI (Relative Strength Index) is 27.69 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.32, which suggests the price will decrease in the coming days. Percent R is at 95.36%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
